Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity

Niloy Jafar Iqbal, Zhonglei Lu, Shun Mei Liu, Gary J. Schwartz, Streamson C. Chua, Jr., Liang Zhu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

When obesity is caused by consumption of a high-fat diet, the tumor suppressor pRb is phosphoinactivated in the neurons of the mediobasal hypothalamus, a brain area critical for energy-balance regulation. However, the functional relevance of pRb phosphoinactivation in the mediobasal hypothalamus to diet-induced obesity remains unknown. Here, we show that inhibiting pRb phosphorylation in the mediobasal hypothalamus can prevent and treat diet-induced obesity in mice. Expressing an unphosphorylable pRb nonselectively in the mediobasal hypothalamus or conditionally in anorexigenic POMC neurons inhibits diet-induced obesity. Intracerebroventricular delivery of US Food and Drug Administration-approved (FDA-approved) cyclin-dependent kinase 4 (CDK4) inhibitor abemaciclib inhibits pRb phosphorylation in the mediobasal hypothalamus and prevents diet-induced obesity. Oral administration of abemaciclib at doses approved for human use reduces fat mass in diet-induced obese mice by increasing lipid oxidation without significantly reducing lean mass. With analysis of recent literature identifying CDK4 as the most abundantly expressed neuronal CDK in the mediobasal hypothalamus, our work uncovers CDK4 as the major kinase for hypothalamic pRb phosphoinactivation and a highly effective central antiobesity target. As three CDK4/6 inhibitors have recently received FDA approval for life-long breast cancer therapy, our study provides a preclinical basis for their expedient repurposing for obesity management.

Original languageEnglish (US)
JournalJCI insight
Volume3
Issue number17
DOIs
StatePublished - Sep 6 2018

Fingerprint

Cyclin-Dependent Kinase 4
Hypothalamus
Obesity
Diet
Cyclin-Dependent Kinase 6
Phosphorylation
Neurons
Obese Mice
Pro-Opiomelanocortin
High Fat Diet
United States Food and Drug Administration
Oral Administration
Phosphotransferases
Fats
Breast Neoplasms
Lipids
Brain

Keywords

  • Metabolism
  • Obesity

Cite this

Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity. / Iqbal, Niloy Jafar; Lu, Zhonglei; Liu, Shun Mei; Schwartz, Gary J.; Chua, Jr., Streamson C.; Zhu, Liang.

In: JCI insight, Vol. 3, No. 17, 06.09.2018.

Research output: Contribution to journalArticle

@article{e4140cd69b8e40098a6547926a32d76a,
title = "Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity",
abstract = "When obesity is caused by consumption of a high-fat diet, the tumor suppressor pRb is phosphoinactivated in the neurons of the mediobasal hypothalamus, a brain area critical for energy-balance regulation. However, the functional relevance of pRb phosphoinactivation in the mediobasal hypothalamus to diet-induced obesity remains unknown. Here, we show that inhibiting pRb phosphorylation in the mediobasal hypothalamus can prevent and treat diet-induced obesity in mice. Expressing an unphosphorylable pRb nonselectively in the mediobasal hypothalamus or conditionally in anorexigenic POMC neurons inhibits diet-induced obesity. Intracerebroventricular delivery of US Food and Drug Administration-approved (FDA-approved) cyclin-dependent kinase 4 (CDK4) inhibitor abemaciclib inhibits pRb phosphorylation in the mediobasal hypothalamus and prevents diet-induced obesity. Oral administration of abemaciclib at doses approved for human use reduces fat mass in diet-induced obese mice by increasing lipid oxidation without significantly reducing lean mass. With analysis of recent literature identifying CDK4 as the most abundantly expressed neuronal CDK in the mediobasal hypothalamus, our work uncovers CDK4 as the major kinase for hypothalamic pRb phosphoinactivation and a highly effective central antiobesity target. As three CDK4/6 inhibitors have recently received FDA approval for life-long breast cancer therapy, our study provides a preclinical basis for their expedient repurposing for obesity management.",
keywords = "Metabolism, Obesity",
author = "Iqbal, {Niloy Jafar} and Zhonglei Lu and Liu, {Shun Mei} and Schwartz, {Gary J.} and {Chua, Jr.}, {Streamson C.} and Liang Zhu",
year = "2018",
month = "9",
day = "6",
doi = "10.1172/jci.insight.123000",
language = "English (US)",
volume = "3",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "17",

}

TY - JOUR

T1 - Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity

AU - Iqbal, Niloy Jafar

AU - Lu, Zhonglei

AU - Liu, Shun Mei

AU - Schwartz, Gary J.

AU - Chua, Jr., Streamson C.

AU - Zhu, Liang

PY - 2018/9/6

Y1 - 2018/9/6

N2 - When obesity is caused by consumption of a high-fat diet, the tumor suppressor pRb is phosphoinactivated in the neurons of the mediobasal hypothalamus, a brain area critical for energy-balance regulation. However, the functional relevance of pRb phosphoinactivation in the mediobasal hypothalamus to diet-induced obesity remains unknown. Here, we show that inhibiting pRb phosphorylation in the mediobasal hypothalamus can prevent and treat diet-induced obesity in mice. Expressing an unphosphorylable pRb nonselectively in the mediobasal hypothalamus or conditionally in anorexigenic POMC neurons inhibits diet-induced obesity. Intracerebroventricular delivery of US Food and Drug Administration-approved (FDA-approved) cyclin-dependent kinase 4 (CDK4) inhibitor abemaciclib inhibits pRb phosphorylation in the mediobasal hypothalamus and prevents diet-induced obesity. Oral administration of abemaciclib at doses approved for human use reduces fat mass in diet-induced obese mice by increasing lipid oxidation without significantly reducing lean mass. With analysis of recent literature identifying CDK4 as the most abundantly expressed neuronal CDK in the mediobasal hypothalamus, our work uncovers CDK4 as the major kinase for hypothalamic pRb phosphoinactivation and a highly effective central antiobesity target. As three CDK4/6 inhibitors have recently received FDA approval for life-long breast cancer therapy, our study provides a preclinical basis for their expedient repurposing for obesity management.

AB - When obesity is caused by consumption of a high-fat diet, the tumor suppressor pRb is phosphoinactivated in the neurons of the mediobasal hypothalamus, a brain area critical for energy-balance regulation. However, the functional relevance of pRb phosphoinactivation in the mediobasal hypothalamus to diet-induced obesity remains unknown. Here, we show that inhibiting pRb phosphorylation in the mediobasal hypothalamus can prevent and treat diet-induced obesity in mice. Expressing an unphosphorylable pRb nonselectively in the mediobasal hypothalamus or conditionally in anorexigenic POMC neurons inhibits diet-induced obesity. Intracerebroventricular delivery of US Food and Drug Administration-approved (FDA-approved) cyclin-dependent kinase 4 (CDK4) inhibitor abemaciclib inhibits pRb phosphorylation in the mediobasal hypothalamus and prevents diet-induced obesity. Oral administration of abemaciclib at doses approved for human use reduces fat mass in diet-induced obese mice by increasing lipid oxidation without significantly reducing lean mass. With analysis of recent literature identifying CDK4 as the most abundantly expressed neuronal CDK in the mediobasal hypothalamus, our work uncovers CDK4 as the major kinase for hypothalamic pRb phosphoinactivation and a highly effective central antiobesity target. As three CDK4/6 inhibitors have recently received FDA approval for life-long breast cancer therapy, our study provides a preclinical basis for their expedient repurposing for obesity management.

KW - Metabolism

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=85062246233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062246233&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.123000

DO - 10.1172/jci.insight.123000

M3 - Article

C2 - 30185666

AN - SCOPUS:85062246233

VL - 3

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 17

ER -